US2020147126A1PendingUtilityA1

Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid

Assignee: ABIOGEN PHARMA SPAPriority: Dec 29, 2005Filed: Dec 27, 2019Published: May 14, 2020

Est. expiryDec 29, 2025(expired)· nominal 20-yr term from priority

Inventors:Sergio Rosini Silvia Trasciatti

A61K 31/728A61K 31/663A61M 5/178A61P 19/02A61P 43/00A61P 19/00A61P 19/04

PatentIndex Score

Cited by

References

Claims

Abstract

Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.

Claims

exact text as granted — not AI-modified

1 - 17 . (canceled) 
     
     
         18 . A pharmaceutical composition comprising clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles, and having a pH of between 4.8 and 6.0. 
     
     
         19 . The composition as claimed in  claim 18 , comprising from 0.5 to 5 mg of clodronic acid or its salts. 
     
     
         20 . The composition as claimed in  claim 18 , comprising sodium clodronate. 
     
     
         21 . The composition as claimed in  claim 18 , comprising from 10 to 30 mg to hyaluronic acid or its salts. 
     
     
         22 . The composition as claimed in  claim 18 , comprising hyaluronic acid or its salts having a molecular weight from 0.4×10 3  to 6×10 3  kDa. 
     
     
         23 . The composition as claimed in  claim 22 , comprising hyaluronic acid or its salts having a molecular weight from 0.4×10 3  to 1.5×10 3  kDa. 
     
     
         24 . The composition as claimed in  claim 21 , comprising sodium hyaluronate. 
     
     
         25 . The composition as claimed in  claim 18 , comprising sodium clodronate and sodium hyaluronate. 
     
     
         26 . The composition as claimed in  claim 18 , which is suitable for the intra-articular administration. 
     
     
         27 . The composition as claimed in  claim 18 , in the form of disposable syringes. 
     
     
         28 . A method of treating osteoarthritis comprising
 administering by intra-articular route an effective amount of a combination of clodronic acid and hyaluronic acid or their salts at a pH of between 4.8 and 6.0 to a subject in need thereof.   
     
     
         29 . The method as claimed in  claim 28  wherein the clodronic acid is in the form of sodium clodronate. 
     
     
         30 . The method as claimed in  claim 28 , wherein the hyaluronic acid is in the form of sodium hyaluronate

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.